Bio-Rad Laboratories and has announced CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first digital PCR system with the CE IVD mark for use as an in vitro diagnostic (IVD) in ...
HERCULES, CA--(Marketwired - Feb 25, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) today announced CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first ...
In the first study 1, clinicians in Wuhan, China observed that a subset of infected individuals who tested negative for COVID-19 using qPCR tested positive using ddPCR. The findings suggest that ddPCR ...
ST. LOUIS--(BUSINESS WIRE)--MOgene, a leading provider of genomics and molecular services worldwide, announced today an expansion of its Digital Droplet technology to include more automation ...
HERCULES, CA--(Marketwired - Jul 29, 2013) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic ...
A) Schema of the single-cell-based droplet digital PCR (sc-ddPCR) system. Using the QX200 ddPCR system, each cell is simply encapsulated in one droplet. Up to 3,000 cells per well can be individually ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...
Bio-Rad Laboratories and has announced CE IVD marking for its QX200™ Droplet Digital™ PCR (ddPCR™) System, the first digital PCR system with the CE IVD mark for use as an in vitro diagnostic (IVD) in ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results